Clincosm LogoSign in Get a demo

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

Sponsor
National Center for Research Resources (NCRR) (NIH)
Overall Status
Unknown status
CT.gov ID
NCT00006199
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

The purpose of this clinical trial is to establish the safest doses for the combination of a farnesyl transferase inhibitor, R115777 plus topotecan in patients with advanced solid tumors, previously treated or beyond standard therapy of clinical benefit. Maximum tolerated dose, dose limiting toxicity and the activity of this combination will be assessed.

This chemotherapy regimen is a two-pronged attack at the way cancer cells replicate. R115777 is a compound that may inhibit cancer cell growth by interfering with the p21 ras oncogene, while topotecan, a topoisomerase-1 inhibitor, works on cancer cells not subject to control by the ras oncogene. Animal studies suggest that the combination may be synergistic. Another advantage is that R115777 can be taken by mouth.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Patients with advanced solid tumors with previous treatment or beyond standard therapy of significant clinical benefit

    • Therapy with no more than 3 prior chemotherapy regimens

    • Radiotherapy to less than 25% of bone marrow volume (no pelvic radiation)

    • Adequate organ function

    • Recovery from the effects of prior chemotherapy and radiation therapy, with at least a 4 week interval. All prior toxicities should have resolved to baseline prior to entry into the study.

    • Good performance status

    • Anticipate life expectancy of at least 6 months

    • Not pregnant or lactating.

    • Sexually active men and women of childbearing age must use adequate contraception.

    • Be able to give signed, written informed consent.

    • No gastrointestinal condition that could affect the absorption of the drug

    • No active infection requiring systemic medical therapy one week prior to chemotherapy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NYU Cancer Institute New York New York United States 10016

    Sponsors and Collaborators

    • National Center for Research Resources (NCRR)

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00006199
    Other Study ID Numbers:
    • NCRR-M01RR00096-1001
    • M01RR000096
    First Posted:
    Sep 11, 2000
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Jan 1, 2004
    Keywords provided by , ,
    solid tumor
    Additional relevant MeSH terms:
    Topotecan
    Tipifarnib

    Study Results

    No Results Posted as of Jun 24, 2005